Reported results
- Research and Development expenses were $34.5 million for the three months ended September 30, 2026.
- General and Administrative expenses were $5.9 million for the three months ended September 30, 2026.
- Net loss was $38.3 million, or $0.43 per share (basic and diluted), for the three months ended September 30, 2026.
- Participants in high-dose cohorts achieved an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) at latest assessment.
- Participants in high-dose cohorts achieved a 44% mean reduction in premature ventricular contractions (PVC) burden at latest assessment.
Guidance
- Lexeo expects to finalize pivotal study design, statistical analysis plan and confirmatory evidence strategy in 1H 2027.
- Lexeo expects to initiate a pivotal study supporting accelerated approval in 2H 2027.
- Cash, cash equivalents, and investments of $219.1 million are expected to provide operational runway into 2028.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.
